Appendix 4E and 2026 Annual Report
Filed with ASX · · 72 pages · English
Summary by 6ix AI
The report highlights a significant increase in revenue from ordinary activities, primarily driven by sales of medicinal cannabis products, although the company reported a loss for the year. The report also discusses the company's strategic focus on European markets and ongoing regulatory developments that may impact future growth. Additionally, the report includes insights into the company's environmental, social, and governance initiatives, emphasizing its commitment to sustainable practices.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Little Green Pharma Ltd. on 6ix
Story so far
Earlier from Little Green Pharma
- Transaction Update and General Meeting Update
- Updated second court date and indicative timetable
- Scheme Update
- Scheme Approved by Cannatrek Shareholders
- Supplementary Scheme Booklet
Later from Little Green Pharma
- Court Approves the Scheme and Scheme Becomes Effective
- Implementation of Merger between LGP and Cannatrek
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Little Green Pharma into a list and get an email when it puts out news.
Follow Little Green Pharma